Literature DB >> 24394306

Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face.

Janet Y Li1, Joan Guitart, Melissa P Pulitzer, Antonio Subtil, Uma Sundram, Youn Kim, Janyana Deonizio, Patricia L Myskowski, Alison Moskowitz, Steven Horwitz, Christiane Querfeld.   

Abstract

We report 7 cases of a CD8 lymphoid proliferation of the ear and face with a cytotoxic T-cell phenotype, but an indolent clinical course. All patients presented with stable or slowly growing asymptomatic lesions on the ear, nose, or lower eyelid. Histopathology showed a dense diffuse dermal infiltrate of small- to medium-sized atypical lymphocytes without destructive features. The lymphocytes were positive for CD3, CD8, β-F1, and TIA-1 and negative for CD4, CD30, CD56, granzyme B, and PD-1. Of note, the proliferation index was low in available cases. All patients remained in complete remission at median follow-up of 14 months regardless of treatment modality. Staging was negative for extracutaneous disease in all patients. The clinically indolent behavior and histopathologic phenotype together with a low proliferation index (10%-15%) emphasize the importance of accurate diagnosis and appropriate clinical management to avoid overtreatment and complications of therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24394306     DOI: 10.1097/DAD.0b013e3182a74c7a

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  2 in total

1.  Long-term follow-up and management of small and medium-sized CD4+ T cell lymphoma and CD8+ lymphoid proliferations of acral sites: a multicenter experience.

Authors:  Pooja Virmani; Sarah Jawed; Patricia L Myskowski; Steven Horwitz; Anna Skripnik Lucas; Alison Moskowitz; Melissa Pulitzer; Jasmine Zain; Steven T Rosen; Christiane Querfeld
Journal:  Int J Dermatol       Date:  2016-11       Impact factor: 2.736

Review 2.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Authors:  Rein Willemze; Lorenzo Cerroni; Werner Kempf; Emilio Berti; Fabio Facchetti; Steven H Swerdlow; Elaine S Jaffe
Journal:  Blood       Date:  2019-01-11       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.